Coralville, IA, United States of America

Mark Aaron Behlke

This inventor holds 84 USPTO granted patents and 51 published patent applications, plus 4 CIPO patents and 25 EPO patents, primarily in Genome Editing Technology (CPC class C12N15-113). Top assignees: Integrated Dna Technologies, Inc., Beckman Research Institute, City of Hope, University of Iowa Research Foundation. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark Aaron Behlke. Retrieved from https://idiyas.com/inventor/mark-aaron-behlke

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 84 (Patent Applications = 51)

% Patents Active = 84.5

CIPO Patents = 4 (Patent Applications = 13)

EPO Patents = 25 (Patent Applications = 36)

Average Co-Inventor Count = 4.2

ph-index = 12

Forward Citations = 597(Granted Patents)

Forward Citations (Not Self Cited) = 435(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Iowa City, IA (US) (2004 - 2006)
Coraville, IA (US) (2014)
Coralville, IA (US) (2005 - 2024)

Company Filing History:

75 out of 111

Integrated Dna Technologies, Inc.

patents

13 out of 692

Beckman Research Institute, City of Hope

patents

7 out of 925

University of Iowa Research Foundation

6. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2004-2026

Loading Chart...

Areas of Expertise:

CRISPR

Genome Editing

Cas9 Mutations

Oligonucleotide Probes

DNA Cleavage

RNA Inhibition

Primer Dimers

Molecular Identification

High-Fidelity Polymerases

Target Enrichment

Gene Expression

Microbial Detection

84 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12723264 - S PYOGENES CAS9 MUTANT GENES AND POLYPEPTIDES ENCODED BY SAME (2026-09-01),

2. 12655422 - METHODS AND COMPOSITIONS FOR INHIBITION OF CRISPR RE-CLEAVAGE EVENTS (2026-06-16),

3. 12618054 - CRISPR/CPF1 SYSTEMS AND METHODS (2026-05-05),

4. 12454684 - Methods using novel CPF1 mutations that enhance the DNA cleavage activity ofsp. CPF1 (2025-10-28),

5. 12378612 - Oligonucleotide-based probes and methods for detection of microbes (2025-08-05),

6. 12351799 - S. pyogenes CAS9 mutant genes and polypeptides encoded by same (2025-07-08),

7. 12168765 - CAS9 mutant genes and polypeptides encoded by same (2024-12-17),

8. 12123033 - Modified double-stranded donor templates (2024-10-22),

9. 12024742 - RNASE H2 mutants that reduce primer dimers and off-target amplification in RHPCR-based amplicon sequencing with high-fidelity DNA polymerases (2024-07-02),

10. 12012433 - Expression and purification of Cas enzymes (2024-06-18),

11. 11999994 - Methods for production and quantification of unique molecular identifier-labeled beads (2024-06-04),

12. 11926866 - Method for detecting on-target and predicted off-target genome editing events (2024-03-12),

13. 11913014 - Cas9 mutant genes and polypeptides encoded by same (2024-02-27),

14. 11566283 - T-enhanced blocking oligonucleotides and baits for improved target enrichment and reduced off-target selection (2023-01-31),

15. 11566282 - T-enhanced blocking oligonucleotides and baits for improved target enrichment and reduced off-target selection (2023-01-31),

Title: The Innovative Journey of Mark Aaron Behlke

Introduction: Mark Aaron Behlke is a pioneering inventor based in Coralville, Iowa. With a passion for pushing the boundaries of science and technology, Behlke has made significant contributions to the field of innovation.

Latest Patents: Behlke holds several patents in the field of biotechnology and molecular biology, focusing on novel methods for gene expression analysis and nucleic acid detection. His recent patents showcase his commitment to advancing research in these critical areas.

Career Highlights: Throughout his career, Behlke has been at the forefront of cutting-edge research, working on groundbreaking projects that have the potential to revolutionize the way we approach genetic analysis. His innovative solutions have garnered recognition from peers in the industry.

Collaborations: Behlke has collaborated with leading research institutions and biotechnology companies to further develop and implement his inventions. His partnerships have been instrumental in bringing his ideas to life and making a tangible impact on the scientific community.

Conclusion: Mark Aaron Behlke's dedication to innovation and his relentless pursuit of scientific excellence have established him as a prominent figure in the world of biotechnology. His work continues to inspire and shape the future of genetic research.

Profile summary based on public USPTO records.